Clinical Trial: Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07037433) titled 'Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity' on June 16.

Brief Summary: The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

Study Start Date: July 29

Study Type: INTERVENTIONAL

Condition: Atherosclerotic Cardiovascular Disease Overweight Obesity

Intervention: DRUG: Maridebart Cafraglutide

Maridebart cafraglutide will be administered SC.

DRUG: ...